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ABSTRACT
Much criticism has been directed at the licencing requirements for medical devices (MDs) as they often result in a lack of
robust evidence to inform health technology assessment (HTA) decisions. To better understand the current international
decisional framework on MD technologies, we undertook three linked research studies: a review of the device regulatory
procedures, a survey of current HTA practices and an empirical comparison of HTA reports of drugs versus MDs. Our
review confirms that current device regulatory processes across the globe are substantially less stringent than drugs. As a
result, international HTA agencies report that they face a number of challenges when assessing MDs, including reliance
on suboptimal data to make clinical and cost-effectiveness decisions. Whilst many HTA agencies have adapted their
processes and procedures to handle MD technology submissions, in our comparison of HTA reports we found little
evidence of the application of methodologies that take account of device-specific issues, such as incremental development.
Overall, our research reinforces the need for better linkage between licencing and HTA and the development and application
of innovative HTA methodologies with the objective of securing faster patient access for those technologies that can be
shown to represent good value for money. © 2017 The Authors. Health Economics Published by John Wiley & Sons, Ltd.
Received 23 February 2016; Revised 6 December 2016; Accepted 7 December 2016
KEY WORDS: medical device; regulation; market access; health technology assessment
1. INTRODUCTION
Health technology assessment (HTA) seeks to synthesise information on the clinical, economic, social and
ethical value of health technologies, including pharmaceuticals, medical devices (MDs), clinical procedures
and organisational systems, used in healthcare, with the aim of informing the formulation of safe and effective
health policies, particularly in relation to reimbursement or coverage decisions (Banta, 2009). However, HTA
and economic evaluation methods have been largely developed with the evaluation of drugs or pharmaceuticals
in mind (Franken et al., 2012; Oortwijn et al., 2010). As a consequence, a number of commentators have
argued the generic application of international HTA methods guidelines to non-drug technologies, especially
MDs, to be inappropriate, and that these methods overlook important differences between drug and devices
(Drummond et al., 2009; Kirisits and Redekop, 2013; Sorenson and Drummond, 2014; Taylor and Iglesias,
2009). In brief, these differences can be broadly characterised under three headings: (i) nature of the (clinical)
evidence base: traditionally lower licencing of requirements for devices than drugs has meant that the clinical
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evidence base for a device may consist of data that are prone to the problems of selection bias and confounding,
with little or no randomised controlled trial (RCT); (ii) nature of the device technology: unlike drugs, devices
often undergo incremental evolution over time that can rapidly change the technology under assessment. Fur-
thermore, as they typically are only one component of a clinical procedure, patient-related outcomes often de-
pend on training and experience of the operator together with the setting in which the device is applied; and
(iii) pricing: MDs pricing is more dynamic compared with drugs because of the market entry of new device prod-
ucts or because of the ways in which procurement takes place in many healthcare systems. Technology manu-
facturers and policymakers are placing increased pressure on the HTA and health economics communities to
develop their current assessment methods to better take account of these features of MDs (Ferrusi et al.,
2009). For example, in recognition of the challenges faced by industry, as well as the growing need for cost-
effective allocation of National Health Service resources, the National Institute for Health and Care Excellence
(NICE) in England and Wales led the development of the Medical Technologies Evaluation Programme
(MTEP), which launched in 2009/2010. However, an analysis of the output of MTEP’s first 3 years suggests that
it has some way to go to meet pre-specified aims of simplifying access to evaluation, speeding up the process and
increasing evaluative capacity for devices within NICE (Chapman et al., 2014).
In response to this background, in 2013 the European Commission under its seventh Framework Programme
funded the ‘Methods for Health Technology Assessment of Medical Technologies (MedTecHTA)’ project with
the overarching aim of improving the existing HTA and economic evaluation methodological framework for
the assessment of MDs (Università Bocconi - CERGAS, 2016). A starting point for the MedTecHTA project
was to review current approaches and methods for the evaluation of MDs under the first of the seven work
packages included in the overall research programme. Three linked research studies were designed: a review
of the international regulatory procedures for devices, a survey of current international HTA practices for de-
vices and an empirical comparison of the application of methods in HTA reports of drugs versus devices. Given
the details of the first two studies having been published elsewhere (Ciani et al., 2015; Tarricone et al., 2014),
here we focus on the third project. The remainder of the paper provides a brief synopsis of the previous research
performed, illustrates the methods and results of the HTA report comparative study and closes with a discussion
that jointly considers the implications of the findings of work package 1. The overarching aims are to provide a
contemporary review and critique of existing regulatory and HTA approaches for MDs and to make informed
recommendations to improve the policy evaluative framework for these technologies.
1.1. Current international regulatory and health technology assessment practices for medical devices
In 2014, Tarricone et al. (2014) investigated current regulatory practices for MDs based on a systematic review
of the literature and on interviews with regulatory agencies across a number of international jurisdictions, in-
cluding the EU (European Commission Directorate-General for Health and Consumers, Health Technology
and Cosmetics unit), the USA (Food and Drug Administration, FDA), Australia (Therapeutic Goods Adminis-
tration), Canada (Health Canada) and China (China Food and Drug Administration). The review shed light on
several issues. First, the framework for device regulation is complex, in no small part because of the great di-
versity of technologies. Second, existing regulatory processes for MDs generate less clinical evidence than the
corresponding processes for drugs. Third, MDs are assigned to one of several regulatory classes, generally
based on the risk associated with the device, the manufacturers’ intended purpose for the device and the de-
vice’s indication for use. In the EU, the European Commission Medical Devices Directive 93/42/EEC defines
four categories of devices, graded according to the risk assessment, considering the following four dimensions:
(i) duration of contact with the patient; (ii) the invasiveness; (iii) the intended use and dependence on an exter-
nal source of energy; and (iv) the location of the anatomical area affected. The device class determines, among
other things, the level of evidence and evaluation required to demonstrate safety and efficacy (e.g. invasive and
high-risk devices require more evidence); however, there are substantial differences in these requirements
across jurisdictions. In particular, and in contrast to the USA, the current system of regulation in EU typically
does not require adequately powered RCTs for the approval of a high-risk device. Fourth, a common approach
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employed to speed up the regulatory process is to allow new devices to claim similarity to other devices already
on the market (e.g. the 510(k) process of the US FDA). The US Supreme Court has acknowledged that substan-
tial equivalence is no guarantee that an MD is safe and effective, and previous authors have suggested that if
some of the 510(k)-cleared devices had been subject to a full pre-market application process, their risks may
have been identified sooner (Campillo-Artero, 2013). Finally, although regulatory processes consistently im-
pose obligations on the manufacturer for post-market surveillance, such post-approval monitoring approaches
are often limited to passive reporting of adverse events for marketed devices.
After better understanding the complexities of MD regulation, we sought to investigate how HTA agencies
evaluate these technologies in the context of recommendations or decisions on their coverage, reimbursement
or use. To meet this aim, Ciani et al. (2015) surveyed the activities for MDs across 36 non-EU HTA agencies.
Data collection was performed in two stages – an agency website assessment using a standardised questionnaire
followed by a semi-structured telephone interview with agency personnel in a subsample of organisations. The
survey had three principle findings. First, although 27 (75%) of the agencies surveyed had adopted HTA-
specific approaches for devices, these were largely organisational (e.g. allocation of specific staff to MDs as-
sessment) or procedural (e.g. convening a specific committee to appraise device evidence and provide policy
advice) in nature. The heterogeneity of agency procedures is an important challenge to manufacturers who want
to embark in the HTA process across several jurisdictions. Second, only one agency (i.e. Department of Science
and Technology in Brazil) had developed methodological guidelines specific to MDs (Ministry of Health of
Brazil, 2014). Finally, in addition to the problem of lack of robust clinical evidence, many interviewed agencies
cited insufficient resources (e.g. budget and skilled employees), lack of coordination between regulatory and
reimbursement bodies, and the inability to generalise findings from evidence syntheses, to be key challenges
in the HTA of devices.
1.2. Comparative assessment of health technology assessment reports on medical devices and drugs
Although limitations of currently available methods for HTA and economic evaluation with respect to MDs
have been highlighted in the scientific literature (Cohen and Billingsley, 2011; Kramer et al., 2012; Sorenson
and Drummond, 2014), no formal comparison of the application of such methods in HTA reports of MDs ver-
sus a comparable sample of HTA reports of drug technologies has been reported. This third study in work pack-
age 1 sought to address the following specific research questions: (i) What is the nature of evidence and
outcomes included in the HTA reports on MDs compared to drugs? (ii) Do the methods (e.g. systematic review
and economic evaluation) applied in HTA reports on MDs and drugs differ? and (iii) How data uncertainty is
addressed and reflected in the technology adoption or policy recommendation in the HTA reports on MDs com-
pared to drugs? Given that cardiovascular is the second largest device sector, following in vitro diagnostics, in
terms of sales, sales growth and market share worldwide (MedTech Europe, 2015), and because we could cap-
italise on the partnership with the European Society of Cardiology within the MedTecHTA project, it was de-
cided to focus this comparison of devices and drugs HTA reports to the field of cardiovascular disease.
2. METHODS
2.1. Identification of health technology assessment reports
Health technology assessment reports were identified by searching the University of York Centre for Reviews
and Dissemination HTA database from 2003 to 2014. The search strategy is listed in Appendix A.
2.2. Selection and screening of reports
We included HTA reports if they assessed a drug or device where the primary indication was cardiovascular
disease (i.e. cerebrovascular, cardiac or peripheral vascular disease). We excluded reports that had a primary
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indication that was not cardiovascular disease; assessed surgical procedures without an MD; addressed a diag-
nosis or prognosis question; were mainly guidelines or overviews that assessed the management of disease in-
dication rather than specific technologies; were not full HTA reports (i.e. a comprehensive systematic
assessment of new or established health technologies that evaluates several dimensions including effect, safety
and cost-effectiveness and often issues relating to ethical, legal, organisational and social consequences;
Velasco et al., 2002); and were not publically available as full text in English. Two members of the research
team (B.W. and R. S. T.) independently screened all titles and abstracts for inclusion. Where there were dis-
agreements about the inclusion of reports, these were discussed and consensus was reached.
2.3. Data extraction and quality assessment
Using a standardised data extraction tool, we sought the following categories of information from the included
HTA reports: general information (e.g. study title, name of agency publishing HTA report), nature of evidence
(e.g. type of clinical or economic studies included), methods applied (e.g. systematic review and economic
evaluation), results (e.g. treatment effect for the all-cause mortality outcome), technology-specific consider-
ations (e.g. incremental innovation of a device or mode of drug administration), methods for handling uncer-
tainty (e.g. sensitivity analysis) and conclusions (e.g. final policy recommendation).
The nature of the primary outcome(s) presented in drug and device reports were categorised as ‘final’ or
‘surrogate’, according to a common definition whereby a surrogate is a biomarker or intermediate outcome
intended to substitute for a patient-relevant outcome (Biomarkers Definitions Working Group, 2001). We ap-
plied this classification to the primary outcomes in each HTA report (i.e. the stated primary outcome of report
or, where not stated, the first outcome discussed in the report). Because cardiovascular disease is a leading
cause of death, we sought to extract the reported treatment effects for both all-cause mortality and, where stated,
the primary outcome. The base case incremental cost-effectiveness ratio was also recorded. The policy recom-
mendations of reports were categorised according to the National Institute for NICE technology appraisal out-
comes (NICE, 2013): (i) recommended: approved for use of an intervention throughout health system, for either
all or specific licenced indications or patient subgroups; (ii) optimised: approved for routine use of specific li-
cenced indications or patient subgroups; (iii) only in research: use of the intervention only in the context of ap-
propriate research; (iv) not recommended: denied approval due to inadequate evidence of clinical or cost-
effectiveness.
We assessed the methods used by HTA reports based on two dimensions of quality: Systematic review
methods were assessed using the Measurement Tool to Assess Systematic Reviews (AMSTAR) (Shea et al.,
2007; Shea et al., 2009), and economic evaluation methods were assessed using a validated checklist
(Drummond et al., 2005). An AMSTAR score is calculated by summing the individual items with a maximum
score of 11 for quality. We used the 10-point Drummond checklist to assess the validity of economic evalua-
tions presented in the included HTA reports. A set of previously described global weighted values associated
with the Drummond checklist items were applied in this study (Drummond and Jefferson, 1996; La Torre et al.,
2010). Where multiple questions from the 35-point checklist related to a single question on the 10-point check-
list, a new weight was calculated by averaging the global weights of the related questions. The maximum
possible economic evaluation quality score was 43.3. The initial list of data extraction items was piloted on a
drug HTA report selected at random. Following this pilot application, we modified items and, where necessary,
updated them with corresponding instructions. The items were further tested on one randomly selected device
report. The final 67 data extraction items are listed in Appendix B. Data from all included HTA reports were
extracted by one member of the research team (B.W.) and independently checked by a second reviewer (A.G.).
2.4. Data analysis
Quantitative data (e.g. number of RCTs included in a report) were summarised across reports using medians,
ranges and percentages. We compared the summary results between MDs and drug HTA reports using non-
parametric statistics (i.e. Mann–Whitney test for continuous and categorical outcomes and Fisher’s exact or
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chi-squared tests for binary outcomes). We sought to compare the size of treatment effects of devices and drugs
by using meta-analyses to pool report mortality and, where stated, primary outcome results. This comparison
would reveal whether specific methodological adjustments would be justified by, on average, significantly dif-
ferent treatment effects produced by device technologies rather than drug technologies in the cardiovascular
field. Descriptive information (e.g. methods of handling uncertainty) was thematically analysed and, where
possible, compared across device and drug reports.
Data were initially extracted into an MS Office Access form, and quantitative and qualitative data were
analysed using STATA© 13.2 StataCorp LP.
3. RESULTS
3.1. Description of included health technology assessment reports
The HTA report selection process is summarised in Figure 1. Out of the 699 HTA reports screened, 45 HTA
reports met the inclusion criteria and were included in the review (Table I). Of these, 18 were MD reports
and 27 were drug reports and were predominantly from Canada (n=15), the UK (n=20) and the USA
(n=8). The included MD and drug reports were broadly similar in terms of their publication date, cardiovascu-
lar indication and issuing agency. All reports considered ‘medium-risk’ or ‘high-risk’ (i.e. class IIa or above)
devices according to the European Commission Medical Device classification system (Council of the European
Communities, 1993).
3.2. Nature of evidence and outcomes
Device reports were more likely to include non-RCT/observational studies than drug reports (44%/48% vs
22%/17%) (Table II). When drug or device reports did consider RCTs, they included a similar number of RCTs
(median of five RCTs per report). However, the average number of patients in RCTs, non-RCTs and observa-
tional studies included in drug reports were threefold larger than in MD reports. The majority of both drug
Figure 1. Summary of the process of selection of health technology assessment (HTA) reports
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Table I. Summary of key characteristics of included health technology assessment reports
Drug (N = 18) Device (N = 27) Drug versus device
n (%) n (%) P-value
Publication date
2003–2008 2 (11) 2 (7) 1.00a
2009–2013 16 (89) 25 (93)
Country of publication
Australia 0 (0) 1 (4) 0.13b
Canada 3 (17) 12 (44)
Republic of Ireland 0 (0) 1 (4)
United Kingdom 12 (67) 8 (30)
United States 3 (17) 5 (19)
Cardiovascular indication
Cerebrovascular 2 (11) 0 (0) 0.20b
Cardiac 12 (67) 19 (70)
Peripheral 4 (22) 8 (30)
Device class
Class I (low risk) NA 0 (0) —
Class IIa (medium risk) NA 3 (11)
Class IIb (medium risk) NA 5 (19)
Class III (high risk) NA 19 (70)
NA, not applicable.
aFisher’s exact test.
bChi-squared test.
Table II. Nature of evidence considered by health technology assessment reports
Drug (N = 18) Device (N = 27) Drug versus device
n (%) Median (range) n (%) Median (range) P-value for %b P-value for mediana
Type of clinical study
RCTs 17 (94) 5 (1; 35) 18 (67) 5 (1; 82) 0.03 0.92
Non-RCTs 4 (22) 5.5 (1; 18) 12 (44) 6 (2; 29) 0.13 0.43
Observational studies 3 (17) 46 (13; 92) 13 (48) 25 (4; 53) 0.03 0.24
Evidence synthesisc 6 (33) 5.5 (5; 30) 8 (30) 5 (1; 15) 0.79 0.30
Otherd 1 (6) 89 (NA) 2 (7) 1.5 (1; 2) 0.81 0.22
Number of patients
RCTs 13 (72) 4203 (34; 66 477) 12 (44) 1482 (291; 35 597) — 0.23
Non-RCTs 3 (17) 4917 (926; 184 372) 5 (19) 836 (79; 12 217) — 0.18
Observational studies 1 (6) 7636 (NA) 7 (26) 646 (76; 13 890) — 0.51
Evidence synthesisc 1 (6) 102 594 (NA) 1 (4) 102 594 (NA) — 0.32
Type of economic evaluation
Cost analysis 1 (6) 5 (NA) 4 (15) 1.5 (1;2) 0.33 0.14
Cost minimisation
analysis
0 (0) — 0 (0) — — —
Cost-effectiveness
analysis
8 (44) 4 (1; 20) 9 (33) 2 (1; 8) 0.45 0.53
Cost–utility analysis 8 (44) 3.5 (1; 8) 9 (33) 1 (1; 4) 0.45 0.11
Cost–benefit analysis 0 (0) — 1 (4) 1 0.41 —
Cost–consequence
analysis
0 (0)x — 0 (0) — — —
RCTs, randomised controlled trial; HTA, health technology assessment.
aMann–Whitney test.
bFisher’s exact test.
cSystematic reviews, meta-analyses and HTA reports.
dRapid reviews and sources of evidence that do not fall into the aforementioned hierarchy of evidence categories.
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reports (17/18, 94%) and device reports (23/27, 85%) examined economic studies in the form of either partial
or full evaluations.
Following the HTA Core Model® classification (EUnetHTA Joint Action 2 Work Package 8, 2016), both
drug and MD reports consistently consider safety, effectiveness and economic evidence (Table III). Device
reports were less likely than drug reports to provide a detailed description of the technology and associated
disease indication. Conversely, 44% (12/27) of MD reports, compared with 6% (1/18) of drug reports,
considered organisational issues. Thirty-six of the 45 reports (82%) considered final outcomes (e.g. all-cause
mortality and cardiovascular mortality), 14/18 (78%) and 22/27 (81%) for drug and MD reports, respectively.
The remaining nine reports considered surrogate outcomes (e.g. Low density lipoprotein (LDL)-cholesterol,
maximal walking distance and mean time to conversion from atrial fibrillation to normal sinus rhythm); five
(19%) of these reports were device reports, and four (22%) were drug reports.
3.3. Data synthesis methods applied by health technology assessment reports
The majority of drug and MD reports included a systematic review of both clinical (37/45, 82%) and
economic studies (19/45, 42%) (Table IV). Drug reports were more likely than MD reports to undertake
a meta-analysis (10/18, 56% vs 9/27, 33%). About 60% of drug and device reports undertook a de novo
model-based economic analysis. The quality of both systematic reviews and economic evaluation methods
appeared to be higher for drug reports than for MD reports. The mean AMSTAR score for drug and
device reports was 7.5 and 5.5, respectively (maximum possible score is 11). For the Drummond
checklist, the mean score for drug and device reports was 29 and 21, respectively (maximum possible
score is 43.3).
The majority of drug (16/18, 89%) and MD (18/27, 67%) reports included consideration of technology-
specific issues. For drugs, dosage, duration of treatment and mode of administration were all commonly
reported. For MDs, the most common issues were healthcare setting of use, learning curve and the device
generation or model. However, these technology-specific issues were typically limited to a brief mention in
the discussion of the HTA report. None of the reports included a formal quantitative analyses to assess how
these issues may impact the clinical or cost-effectiveness of the device.
About 60% of drug and MD reports undertook uncertainty evaluation in their clinical and economic
effectiveness sections. For both, the most commonly considered methods were sensitivity analyses, either
deterministic or probabilistic; use of 95% confidence intervals; and reporting of P-values.
3.4. Size of treatment effects and economic outcomes
We sought to compare drug and MD reports based on pooling across reports the clinical treatment effect on all-
cause mortality and incremental cost-effectiveness ratio. However, the types of clinical and economic outcomes
Table III. EUnetHTA HTA core model® dimensions in HTA reports
Drug (N = 18) Device (N = 27) Drug versus device
n (%) n (%) P-valuea
Health problem and current use of technology 15 (83) 10 (37) <0.001
Description and technical characteristics of technology 15 (83) 8 (30) <0.001
Safety 12 (67) 17 (63) 0.80
Clinical effectiveness 17 (94) 24 (89) 0.64
Cost and economic evaluationb 13 (72) 20 (74) 1.00
Ethical aspects 1 (6) 1 (4) 1.00
Organisational aspects 1 (6) 12 (44) <0.001
Social aspects 5 (28) 3 (11) 0.24
Legal aspects 1 (6) 1 (4) 1.00
aFisher’s exact test.
bCount includes a report if it included a systematic review of economic analyses or de novo economic model.
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presented across reports, outcome metrics (e.g. odds ratio and hazard ratio) and definition (e.g. all-cause
mortality, cardiovascular mortality and vascular death) and point of follow-up (e.g. 7 days, 30 days and
6 months) were highly heterogeneous. Therefore, pooling of treatment effects across reports in this study
was deemed inappropriate. A proportion of drug (4/18, 22%) and MD (7/27, 26%) reports included a pooled
value for all-cause mortality based on a meta-analysis. Ten (56%) drug and 16 (59%) device reports presented
a base case incremental cost-effectiveness ratio. There was no evidence of substantive difference in magnitude
of mortality benefit or the cost-effectiveness ratio for the experimental technologies (compared with control) in
MD reports compared with drug reports.
Table IV. Evidence synthesis methods of HTA reports
Method
Drug (N = 18) Device (N = 27)
Drug versus
Device P-value a
Total
N
n
(%)
Total
N n (%)
Methods of data synthesis
Systematic review of clinical outcomes 18 14 (78) 27 23 (85) 0.52
Meta-analysis 18 10 (56) 27 9 (33) 0.14
Systematic review of economic evaluations 18 9 (50) 27 10 (37) 0.39
Economic model 18 11 (61) 27 17 (63) 0.90
AMSTAR (systematic review quality)
Was an ‘a priori’ design provided? 15 13 (87) 24 12 (50) 0.04
Was there duplicate study selection and data extraction? 15 13 (87) 24 10 (42) 0.01
Was a comprehensive literature search performed? 15 14 (93) 24 20 (83) 0.78
Was the status of publication (i.e. grey literature) used as an inclusion
criterion?
15 10 (67) 24 18 (75) 0.65
Was a list of studies (included and excluded) provided? 15 12 (80) 24 8 (33) <0.001
Were the characteristics of the included studies provided? 15 10 (67) 24 20 (83) 0.36
Was the scientific quality of the included studies assessed and
documented?
15 14 (93) 24 17 (71) 0.078
Was the scientific quality of the included studies used appropriately in
formulating conclusions?
15 10 (67) 24 13 (54) 0.32
Were the methods used to combine the findings of studies appropriate? 15 9 (60) 24 9 (38) 0.17
Was the likelihood of publication bias assessed? 15 6 (40) 24 3 (13) 0.12
Was the conflict of interest included? 15 1 (7) 24 2 (8) 1.00
Total score – mean (standard deviation) 15 7.5 (2.2) 24 5.5 (2.7) 0.04b
Drummond checklist (economic evaluation quality)
Was a well-defined question posed? 11 4 (36) 17 8 (47) 0.71
Was a comprehensive description of the competing alternatives given? (i.e.
can you tell who did what to whom, where and how often?)
11 11 (100) 17 11 (65) 0.06
Was the effectiveness of the programmes or services established? 11 7 (64) 17 8 (47) 0.46
Were all the important and relevant costs and consequences for each
alternative identified?
11 7 (64) 17 10 (59) 1.00
Were costs and consequences measured accurately in appropriate physical
units (e.g. hours of nursing time, number of physician visits, lost work-
days and life-years gained)?
11 7 (64) 17 8 (47) 0.46
Were costs and consequences valued credibly? 11 10 (91) 17 12 (71) 0.36
Were costs and consequences adjusted for differential timing? 11 8 (73) 17 9 (53) 0.44
Was an incremental analysis of costs and consequences of alternatives
performed?
11 11 (100) 17 9 (53) 0.01
Was allowance made for uncertainty in the estimates of costs and
consequences?
11 10 (91) 17 10 (59) 0.10
Did the presentation and discussion of study results include all issues of
concern to users?
11 8 (73) 17 10 (59) 0.69
Total Weighted Score – mean (standard deviation) 11 29 (7.1) 14 21 (9.2) 0.03b
HTA, health technology assessment; AMSTAR, Measurement Tool to Assess Systematic Reviews.
aP-value calculated using Fisher’s exact test.
bP-value calculated using Mann–Whitney U-test.
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3.5. Policy recommendations made by health technology assessment reports
Only a minority of reports (5/18, 28% drug, and 6/27, 22% MDs) included a policy recommendation (Table V).
Where reported, there was no evidence of difference in the type of recommendation provided by authors of drug
or MD reports. However, a higher proportion of MD reports (83% vs 21%) recommended ‘optimised’ adoption
indicating that, probably because of pre-market evidence or evidence quality gaps or need to understand use in
practice, for devices there is more room for streamlining the indications at the time of the assessment.
4. DISCUSSION
The development of new and innovative MDs plays a central role in the management of disease and promotion
of health. In 2015, the global market was valued at €210 billion, up from €150 billion in 2010 and projected to
reach €403 billion by 2018, with an approximate compound growth rate of 4.4% per year. Western Europe
represents approximately 25% of the global MD market, with Germany leading the market followed by
France, the UK and Italy (Cunningham et al., 2015). However, there are still important challenges that currently
face the licencing and reimbursement pathways of MDs. Much criticism has been raised, for instance, by a
number of high-profile device recalls in recent years (Thompson et al., 2011; Zuckerman et al., 2011), because
of safety issues that have included breast implants (Lahiri andWaters, 2006), specific types of artificial hips
(Curfman and Redberg, 2011) and implantable cardioverter-defibrillator leads (Maisel, 2008).
In response to this ongoing debate, we undertook a comprehensive review of current international licencing
and HTA practices for MDs. Our research highlights a number of important findings. First, although we
observed differences in the balance of requirements across regulators in their reliance of pre-market and
post-market approval, our study confirms that, across the globe, current regulatory processes are often substan-
tially less stringent than drugs. This claim was for the first time confirmed by the comparative assessment of
MD HTA reports versus drug HTA reports, showing a significantly higher proportion of MD reports including
observational and non-RCT evidence based on smaller clinical studies. Whilst there is currently no single
harmonised international classification for devices, regulators appear to consistently relate their evidential
requirements for licencing to the level of patient risk associated with the use of different categories of device.
For example, the US FDA is more likely than other international regulators to require a pre-market RCT for a
high-risk (e.g. class III) implantable product.
Second, our interviews with HTA agencies and review of their reports confirmed that this lack of clinical
evidence generated in response to regulatory requirements for MDs leads to difficulties in conducting HTAs,
which in some jurisdictions can create delays in funding and patient access. Such challenges include capacity
or expertise gap and methodological difficulties in the use of observational data to make reliable effectiveness
and cost-effectiveness assessment for a device. This particular aspect is illustrated by the lower methodological
quality observed in MDs HTA reports than drug reports as shown in our comparative study.
Table V. Policy recommendations made by health technology assessment reportsb
Drug (N = 18) Device (N = 27) Drug versus device
n (%) n (%) P-valuea
Recommended 1 (20) 0 (0) 0.26
Optimised 1 (20) 5 (83)
Only in research 1 (20) 0 (0)
Not recommended 2 (40) 1 (17)
Not reported 13 (72) 21 (78)
aChi-squared test.
bCategorised according to the National Institute for Health and Care Excellence technology appraisal decision outcomes.
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Third, many HTA agencies have developed specific organisational structures and processes for the handling
of their evaluation of devices. Heterogeneity of agency procedures is a disadvantage for manufacturers who
need to set up and prepare for different submissions. Nevertheless, we found little or no evidence of the
application of HTA methodologies to quantitatively take account of the specificities of devices. When looking
at the empirical application of methods in HTA reports, we found that MD reports are more likely than drug
reports to consider organisational aspects of the implementation of health technologies in confirmation of the
critical role played by setting-related, institution-related and operator-related aspects in shaping devices’
effectiveness. Although HTA reports often acknowledged MD-specific issues (i.e. organisational factors,
learning curve and combination of observational and trial evidence), however and quite disappointingly they
fail to assess the impact of these MD-specific technology issues in terms of their quantitative impact on cost-
effectiveness of the device or uncertainty.
Whilst the systematic approach to the selection, data extraction and analysis of included HTA reports
strengthens the findings of our study, the relatively small number of eligible documents, published in the En-
glish language and related to cardiovascular disease, may not be generalisable across other medical conditions.
However, given the relevance of MD technologies in cardiovascular disease both economically and therapeu-
tically, it is likely that if any methodological development in the evaluation of devices is adopted, it will be im-
plemented in this specific disease area. Additional comparative analyses of drug versus MD HTA reports in
other medical conditions may help clarify our findings.
Our findings have important implications for both regulators, HTA decision makers, manufacturers and clin-
ical researchers in order to improve and speed up the process of assessment, thereby securing faster patient ac-
cess for those devices that can be shown to be safe and cost-effective. First of all, whilst it seems appropriate
that the type of evidence required prior to approval should match the potential risk of a new device, more strin-
gent requirements to provide clinical data for the efficacy and safety are needed for moderate-risk to high-risk
devices. Appropriate methodological choices should be implemented in order to choose trial designs that allow
to tackle specific challenges raised by the clinical evaluation of MDs (Bernard et al., 2014). Linked to this is the
need for international harmonisation of regulatory requirements, with efforts to set common risk classification
rules. Furthermore, post-marketing surveillance is particularly important in the case of devices, not just for
safety monitoring but also to go beyond efficacy demonstrated in a trial setting and assess effectiveness in reg-
ular use. Collection and promotion of access to device and user real-world data should be encouraged to pro-
vide additional information not only on adverse events but also on learning curve and organisational impact of
MDs, to facilitate reassessment of the technology when it becomes established in the routine practice. There is
the need and the opportunity for better linkage between current licencing and HTA processes. Although the ob-
jectives of licensors and HTA bodies are distinct, in most international jurisdictions it is HTA that drives
healthcare system funding and therefore acts as the de facto barrier to MD access (Tsoi et al., 2013). This is
particularly true for devices first licenced in the EU where manufacturers will often be faced with developing
further clinical and economic evidence for HTA bodies in order to secure reimbursement. The system of ap-
proval based on substantial equivalence (e.g. the US 510(k) approval process) has already been recommended
to be replaced with an integrated pre-market and post-market regulatory framework that effectively provides a
reasonable assurance of safety and effectiveness throughout the device life cycle (Heneghan and Thompson,
2012; Sorenson and Drummond, 2014). A potential collaborative model of future device regulation is the
MaRS Excellence in Clinical Technology Evaluation (EXCITE) programme currently operating in Ontario
(MaRS, 2011). In the EXCITE programme, device manufacturers can have discussions with both regulators
(Health Canada) and HTA (Ontario Office of Health Technology) bodies in order to co-design clinical trial pro-
tocols to meet the needs of both the regulator and the HTA body. A ’parallel submission’ to both decision-
making authorities is then encouraged and supported. Ongoing EXCITE device projects include electrical stim-
ulation for upper limb movements in stroke patients, home sleep apnea event detector and RNA disruption as-
say for early prediction of complete response to chemotherapy in breast cancer patients (Levin, 2015). In 2010,
the US FDA and the Centers for Medicare and Medicaid Services proposed a partial alignment of their respec-
tive review processes for new medical products. The two institutions have recently announced that they will be
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implementing and extending indefinitely the Parallel Review of MDs pilot programme, thus allowing product
sponsors who seek a national coverage determination from the Centers for Medicare and Medicaid Services to
request that the review begins earlier, concurrently with the later stages of the FDA review process. The pro-
posed aligned system of evidence generation is believed to lead to time-saving, uncertainty reduction in the
clinical development path and faster market uptake but also to promote better evidence generation that ad-
dresses simultaneously the information needs of regulators, payers, patients and clinicians (Messner and
Tunis, 2012). In Europe, the Shaping European Early Dialogues project has been developed as a pilot platform
to facilitate the opportunity of early dialogue with the regulator (i.e. European Medicines Agency), selected
European HTA agencies and industry (Harousseau et al., 2015). Of the 11 early dialogues performed so far,
three have concerned MD submissions. A relatively simple but potentially highly effective initiative has been
for regulators to make their documents and processes more available to HTA bodies (Berntgen et al., 2014).
The health service research community needs to extend existing RCT and HTA methods to effectively take
account of the specific issues of devices. The importance of such methodological innovation is highlighted in
the recent guideline for MDs developed by EUNetHTA (EUnetHTA, 2015). Two examples of methodological
developments for handling of device-specific issues produced from the MedTecHTA programme are detailed in
other contribution to this Health Economics supplement (Schnell-Inderst et al., 2017; Varabyova et al., 2016).
Relatedly, a development of the necessary capacity within the HTA agencies is needed in order to implement
these under-used approaches.
Current licencing and HTA systems are continuously evolving with the specific aims of assessing safety,
performance, efficacy, effectiveness and added value of health technologies, including MDs. Little
harmonisation has been observed so far between the two, whilst based on the findings of our research projects,
we would encourage a continuous dialogue among all parties involved to agree on the types of clinical and
health economic evidence needed for licencing and for funding to new devices, to strengthen the evidence base
and the development and application of innovative HTA methodologies and to shorten the overall time needed
for patients to access cost-effective devices.
APPENDIX A: SEARCH STRATEGY
APPENDIX B: DATA EXTRACTION TOOL, FIELDS AND CODING
#1 (*) and (Full publication record: ZDT) IN HTA FROM 2008 TO 2013
#2 MeSH DESCRIPTOR cardiovascular diseases EXPLODE ALL TREES
#3 #1 AND #2
Field name Type Description
1 ID Continuous Unique identifier
2 RevName Open-ended Name of researcher performing
data extraction
3 ExDate Open-ended Date of extraction
4 Date Date/time Date of publication
5 Record Continuous Corresponding search record number set by the
Centre for Reviews and Dissemination
6 Agency Open-ended Name of agency publishing HTA report
7 Country Open-ended Name of country publishing HTA report
8 Invent Categorical Type of intervention:
• Drug or
• Medical Device
9 Class Open-ended Device assignment to a specified regulatory
class based on the level of control necessary
(Continues)
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Field name Type Description
to assure the safety and effectiveness
(e.g. Class I, Class II and Class III)
10 Therapy Categorical Cardiovascular therapy area targeted by the intervention:
• Cerebrovascular
• Coronary or
• Peripheral
11 Problem Open-ended Decision problem addressed in HTA report
12 Participants Open-ended Patient, population of patients, problem
13 Intervention Open-ended List interventions, indicate if STA (single
technology assessment) or MTA
(multiple technology assessment)
14 Outcomes Open-ended List of all outcomes evaluated in report
15 Comparators Open-ended Comparison (another therapy or placebo)
16 Licensing Date/time Date of licencing
17 Clinical Open-ended Type of clinical studies included
18 Clinical_num Open-ended Number of studies (by type, e.g. RCT or non-RCT)
19 Clinical_patient Open-ended Number of patients included in each clinical scenario bucket
20 Econ Open-ended Type of economic evaluation included
21 Econ_num Open-ended Number of each type of economic evaluation
22 Design1 Binary Systematic review of clinical outcomes (yes/no)
23 Design2 Binary Systematic review without meta-analysis (yes/no)
24 Design3 Binary Systematic review with meta-analysis (yes/no)
25 Design4 Binary Include economic evaluation/economic model (yes/no)
26 Amstar1 Categorical A Measurement Tool to Assess Systematic
Reviews (AMSTAR) Checklist
Item 1: Was an ‘a priori’ design provided,
• No
• Yes
• Can’t answer
• Not applicable
27 Amstar2 Categorical A Measurement Tool to Assess
Systematic Reviews (AMSTAR)
Checklist Item 2: Was there
duplicate study selection and data extraction?
• No
• Yes
• Can’t answer
• Not applicable
28 Amstar3 Categorical A Measurement Tool to Assess
Systematic Reviews (AMSTAR)
Checklist Item 3: was
a comprehensive literature search performed?
• No
• Yes
• Can’t answer
• Not applicable
29 Amstar4 Categorical A Measurement Tool to Assess Systematic
Reviews (AMSTAR) Checklist Item
4: Was the status of publication
(i.e. grey literature) used as an inclusion criterion?
30 Amstar5 Categorical A Measurement Tool to Assess
Systematic Reviews (AMSTAR)
Checklist Item 5: Was a
list of studies (included and excluded) provided?
• No
• Yes
• Can’t answer
• Not applicable
(Continues)
(Continued)
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Field name Type Description
31 Amstar6 Categorical A Measurement Tool to Assess
Systematic Reviews (AMSTAR)
Checklist Item 6: Were the
characteristics of the included studies provided?
• No
• Yes
• Can’t answer
• Not applicable
32 Amstar7 Categorical A Measurement Tool to Assess Systematic
Reviews (AMSTAR) Checklist Item
7: Was the scientific quality of the
included studies assessed and documented?
• No
• Yes
• Can’t answer
• Not applicable
33 Amstar8 Categorical A Measurement Tool to Assess Systematic Reviews
(AMSTAR) Checklist Item 8: Was the scientific
quality of the included studies used
appropriately in formulating conclusions?
• No
• Yes
• Can’t answer
• Not applicable
34 Amstar9 Categorical A Measurement Tool to Assess Systematic
Reviews (AMSTAR) Checklist Item
9: Were the methods used
to combine the findings of studies appropriate?
• No
• Yes
• Can’t answer
• Not applicable
35 Amstar10 Categorical A Measurement Tool to Assess
Systematic Reviews (AMSTAR)
Checklist Item 10: Was the
likelihood of publication bias assessed?
• No
• Yes
• Can’t answer
• Not applicable
36 Amstar11 Categorical A Measurement Tool to Assess
Systematic Reviews (AMSTAR)
Checklist Item 11: Was
the conflict of interest included?
37 Drummond1 Binary Drummond checklist for assessing
economic evaluations item
1: Was a well-defined
question posed? (yes/no)
38 Drummond2 Binary Drummond checklist for assessing
economic evaluations item
2: Was a comprehensive
description of
the competing alternatives given? (i.e. can you
tell who did what to whom, where and how often? (yes/no)
39 Drummond3 Binary Drummond checklist for assessing
economic evaluations item 3: Was
the effectiveness of the programmes or
services established
(Continues)
(Continued)
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Field name Type Description
40 Drummond4 Binary Drummond checklist for assessing economic
evaluations item
4: Were all the important and relevant costs
and consequences for each
alternative identified? (yes/no)
41 Drummond5 Binary Drummond checklist for
assessing economic
evaluations item
5: Were costs
and consequences
measured accurately in appropriate physical units
(e.g. hours of nursing time, number of physician
visits, lost work-days and gained life-years)? (yes/no)
42 Drummond6 Binary Drummond checklist for assessing economic
evaluations item 6: Were costs and consequences
valued credibly? (yes/no)
43 Drummond7 Binary Drummond checklist for assessing economic
evaluations item 7: Were costs and
consequences adjusted for differential timing? (yes/no)
44 Drummond8 Binary Drummond checklist for assessing economic
evaluations item 8: Was an incremental
analysis of costs and consequences of
alternatives performed? (yes/no)
45 Drummond9 Binary Drummond checklist for assessing economic
evaluations item 9: Was allowance made for uncertainty in
the estimates of costs and consequences? (yes/no)
46 Drummond10 Binary Drummond checklist for assessing economic evaluations
item 10: Did the presentation and discussion of study results
include all issues of concern to users? (yes/no)
47 Drug_specs Open-ended Technology-specific methods and considerations for drugs (e.g.
oral versus injectable)
48 Device_specs Open-ended Technology-specific methods and considerations for devices (e.g.
learning curve, incremental evolution)
49 Uncertainty_cl Binary Did the clinical analysis take uncertainty into account? (yes/no)
50 Uncertainty_cl2 Open-ended If yes to Item 59, how did the clinical analysis
take uncertainty into account?
51 Uncertainty_ee Binary Did the economic analysis take
uncertainty into account? (yes/no)
52 Uncertainty_ee2 Open-ended If yes to Item 61, how did the economic
analysis take uncertainty into account?
53 Res_Core1 Binary Indicate if this element of HTA Core Model is reported in
the results: Health problem and current use of technology (yes/no)
54 Res_Core2 Binary Indicate if this element of HTA Core Model is reported
in the results: Description and technical characteristics
of technology (yes/no)
55 Res_Core3 Binary Indicate if this element of HTA Core Model is
reported in the results: Safety (yes/no)
56 Res_Core4 Binary Indicate if this element of HTA Core Model is
reported in the results: Clinical effectiveness (yes/no)
57 Res_Core5 Binary Indicate if this element of HTA Core Model is reported in the
results: Cost and economic evaluation (yes/no)
58 Res_Core6 Binary Indicate if this element of HTA Core Model is
reported in the results: Ethical aspects
59 Res_Core7 Binary Indicate if this element of HTA Core Model is
reported in the results: Organisational aspects (yes/no)
60 Res_Core8 Binary Indicate if this element of HTA Core Model is
reported in the results: Social aspects (yes/no)
61 Res_Core9 Binary Indicate if this element of HTA Core Model is
reported in the results: Legal aspects (yes/no)
(Continues)
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